Mylan says Teva offer too low; criticizes stock, growth prospects

(Reuters) – Mylan NV rejected Teva Pharmaceutical Industries Ltd’s $40 billion takeover offer on Monday, saying in a scathing letter that it grossly undervalued the company and that Mylan has no interest in payment in what it termed “high-risk” Teva stock.




Source: Business

Leave a Reply

Your email address will not be published. Required fields are marked *

4 × 3 =